Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 16/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | ROS1 | P08922 | 3/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767938 | 0.97 | NTRK1 (0.45) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL767939 | 0.97 | NTRK1 (0.45) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL768426 | 0.96 | NTRK1 (0.43) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL767684 | 0.91 | IGF1R (0.44) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL767683 | 0.91 | IGF1R (0.44) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL774061 | 0.89 | NTRK1 (0.43) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL767559 | 0.88 | NTRK1 (0.42) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL772593 | 0.87 | NTRK1 (0.47) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL768792 | 0.87 | NTRK1 (0.44) | IGF1RCYP3A4NTRK1RETROS1 | |
| SCHEMBL10283915 | 0.87 | NTRK1 (0.44) | IGF1RCYP3A4NTRK1RETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | IGF1R 2381/4885CYP3A4 1201/4885NTRK1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.